Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dostarlimab + belrestotug
- Development stage
- Discontinued
- Lead developer
- iTeos Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Dostarlimab + belrestotug is a combination of two monoclonal antibodies developed for the treatment of cancer, specifically non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC). Dostarlimab is an anti–PD-1 antibody that blocks the programmed death-1 receptor on T cells, thereby enhancing immune-mediated tumor cell killing. Belrestotug (formerly EOS-448 or GSK4428859A) is an Fc-active human IgG1 monoclonal antibody targeting TIGIT, an inhibitory receptor that suppresses adaptive and innate immune responses against tumors. The rationale for combining these agents was to achieve synergistic immunomodulation by simultaneously blocking PD-1 and TIGIT pathways to enhance antitumor immunity. Clinical trials showed improved objective response rates compared to monotherapy but failed to demonstrate a meaningful benefit in progression-free survival; as a result, development has been discontinued[3][5][6][7][8].
- Brand names
- Jemperli
- Other names
- belrestotug + dostarlimabbelrestotug-dostarlimab combination
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)TIGIT (T cell immunoreceptor with Ig and ITIM domains)
Beyond the preview
Go deeper on dostarlimab + belrestotug.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dostarlimab + belrestotug.